In a Phase Ib/II trial led by Naval Daver, M.D., professor of Leukemia, patients with newly diagnosed CD123-positive acute myeloid leukemia (AML) who were unable to undergo intensive chemotherapy had strong response rates from the triplet combination of venetoclax, azacitidine and pivekimab sunirine (PVEK).
“This triplet regimen may represent a significant step forward for older patients with CD123-positive AML who are not candidates for intensive chemotherapy,” Daver said. “The remission and MRD rates we observed are very encouraging and support further development in larger trials.”
In the Phase I/II registrational CADENZA study led by Naveen Pemmaraju, M.D., professor of Leukemia, PVEK monotherapy achieved high response rates in a subgroup of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) – a rare and aggressive blood cancer – and other blood cancers.